CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Patient reported outcomes for the CANDOR trial for multiple myeloma

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC

AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

COVID-19 and breast cancer: How should we treat our patients?

Reducing damage to swallowing muscles during radiotherapy for head and neck cancers

Comment: JAVELIN-100 for metastatic urothelial cancer

HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma